中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
5期
576-577
,共2页
侯芸华%张永利%麦玉洁%李宁宁
侯蕓華%張永利%麥玉潔%李寧寧
후예화%장영리%맥옥길%리저저
白血病,淋巴细胞,急性%瘦素%细胞因子类
白血病,淋巴細胞,急性%瘦素%細胞因子類
백혈병,림파세포,급성%수소%세포인자류
Leukemia,lymphocytic,acute%Leptin%Cytokines
目的 研究急性淋巴细胞白血病(ALL)患者血清瘦素水平变化的临床意义.方法 选取ALL患者及健康成人各20例,分别以放射免疫法测定其血清瘦素水平,并在化疗2个周期后再次测定ALL患者血清瘦素水平.结果 ALL组化疗前血清瘦素水平明显低于健康对照组[(19.2±4.5)μg/L比(33.9±6.2)μg/L,P<0.05].ALL组化疗后血清瘦素水平[(28.9±5.5)μg/L]明显高于化疗前(P<0.05).结论 ALL患者血清瘦素水平较健康成人低,经化疗缓解后,其血清瘦素水平明显增高.血清瘦素水平可作为判断ALL治疗效果的有效指标之一.
目的 研究急性淋巴細胞白血病(ALL)患者血清瘦素水平變化的臨床意義.方法 選取ALL患者及健康成人各20例,分彆以放射免疫法測定其血清瘦素水平,併在化療2箇週期後再次測定ALL患者血清瘦素水平.結果 ALL組化療前血清瘦素水平明顯低于健康對照組[(19.2±4.5)μg/L比(33.9±6.2)μg/L,P<0.05].ALL組化療後血清瘦素水平[(28.9±5.5)μg/L]明顯高于化療前(P<0.05).結論 ALL患者血清瘦素水平較健康成人低,經化療緩解後,其血清瘦素水平明顯增高.血清瘦素水平可作為判斷ALL治療效果的有效指標之一.
목적 연구급성림파세포백혈병(ALL)환자혈청수소수평변화적림상의의.방법 선취ALL환자급건강성인각20례,분별이방사면역법측정기혈청수소수평,병재화료2개주기후재차측정ALL환자혈청수소수평.결과 ALL조화료전혈청수소수평명현저우건강대조조[(19.2±4.5)μg/L비(33.9±6.2)μg/L,P<0.05].ALL조화료후혈청수소수평[(28.9±5.5)μg/L]명현고우화료전(P<0.05).결론 ALL환자혈청수소수평교건강성인저,경화료완해후,기혈청수소수평명현증고.혈청수소수평가작위판단ALL치료효과적유효지표지일.
Objective To investigate the level of plasma leptin in patients with acute lymphoblastic leukemia (ALL) , and to compare the difference of plasma leptin levels in patients with ALL respectively before and after chemotherapy in order to discuss the relationship between ALL and plasma leptin level. Methods There were 20 cases in ALL group and 20 normal persons in control group. We examined the expression of the levels of leptin in plasma with ALL patients respectively before (group A) and after 2 circles chemotherapy (group C) and normal persons (group B) using radioimmunoassay method. Results The leptin levels of group A and B were( 19. 2 ± 4.5) n,g/L and (33.9 ±6. 2) p,g/L respectively with significant statistical difference. The leptin levels of group A and C were(19.2 ±4.5)μg/L and (28.9 ±5.5)μg/L respectively. Conclusions The plasma leptin level in patients with ALL is lower than that in normal persons. After chemotherapy the plasma leptin level is markedly higher than before. The leptin level of plasma can be used as a helpful indicator to evaluate the therapeutic effect of patients with ALL.